Determinants of recurrent toxicity-driven switches of highly active antiretroviral therapy. The ATHENA cohort

AIDS

Volumn 16, Issue 5, 2002, Pages 737-745

  Dieleman, Jeanne P ^a,e   Jambroes, Marielle ^b,c,e   Gyssens, Inge C ^a,e   Sturkenboom, Miriam C J M ^a,e   Stricker, Bruno H Ch ^a,d,e   Mulder, Wilhelmina M C ^c,e   De Wolf, Frank ^c,e   Weverling, Gerrit Jan ^c,e   Lange, Joep M A ^b,c,e   Reiss, Peter ^b,c,e   Brinkman, Kees ^e  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Natl AIDS Therapy Evaluation Centre   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d Inspectorate for Health Care   (Netherlands)

^e ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

Author keywords

Cumulative incidences; HAART; Highly active antiretroviral therapy; Risk factors; Toxicity; Treatment switch

Indexed keywords

ANTIRETROVIRUS AGENT; INDINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR;

ADULT; ARTICLE; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; NEUROPATHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECURRENT DISEASE; RISK BENEFIT ANALYSIS; RISK FACTOR; TREATMENT PLANNING; VIRUS INHIBITION;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MIDDLE AGED; RECURRENCE; REVERSE TRANSCRIPTASE INHIBITORS; VIRAL LOAD;

EID: 0037192573     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200203290-00009     Document Type: Article

References (25)

1. Patient compliance and drug failure in protease inhibitor monotherapy
2. Attaining higher goals in HIV treatment: The central importance of adherence
3. HIV-protease inhibitors
4. HIV-1 protease inhibitors. A review for clinicians
5. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study
6. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients
7. Incidence of discontinuation of highly active antiretroviral combination therapy (HAART) and its determinants
8. Outcome of a second-line protease inhibitor-containing regimen in patients failing or intolerant of a first highly active antiretroviral therapy
9. Reasons for modification and discontinuation of antiretrovirals: Results from a single treatment centre
10. Antiretroviral therapy in adults. Updated recommendations of the International AIDS Society-USA Panel
11. 1998 Revision to the British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals
12. British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals
13. Sex-dependent pbarmacokinetics of indinavir: In vivo and in vitro evidence
14. The relationship of ritonavir plasma levels and side effects: Implications for therapeutic drug monitoring
15. Indinavir pharmacokinetics and parmacodynamics in children with human immunodeficiency virus infection
16. Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients
17. CBO guidelines: Antiretroviral therapy in the Netherlands
18. The effect of treatment intensification in HIV-infectlon: A study comparing treatment with ritonavir/saquinavir and ritonavir/saquinavir/stavudine
19. Revision of the Cdc surveillance case definition for acquired immunodeficiency syndrome
20. Substituting nevirapine for protease inhibitor because of intolerance
21. Benefits and risks of switching from protease inhibitors to nevirapine with stable background therapy in patients with low or undetectable viral load: A multicentre study
22. Substitution of a nonnucleoside reverse transcriptase inhibitor for a protease inhibitor in the treatment of patients with undetectable plasma human immunodeficiency virus type 1 RNA
23. Risks and benefits of replacing protease inbibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy
24. Influence of gender on indinavir pharmacokinetics
25. Antiretroviral therapy for HIV infection in 1998: Updated recommendations of the International AIDS Society-USA Panel